Advaxis

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2021 and provides a business update.

Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agreement with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock. The shares to be sold will have an aggregate stated value of $5,000,000. Each share of the Series D preferred stock has a purchase price of $4.75, representing an original issue discount (“OID”) of 5% of the stated value. The shares of Series D preferred stock are convertible into shares of the Company's common stock, upon the occurrence of certain events, at a conversion price of $0.25 per share of common stock. The conversion, at the option of the stockholder, may occur at any time following the receipt of the stockholders' approval for a reverse stock split. The Company will be permitted to compel conversion of the Series D preferred stock after the fulfillment of certain conditions and subject to certain limitations. The Series D preferred stock will also have a liquidation preference over the common stock, and may be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. The Company and the holders of the Series D preferred stock will also enter into a registration rights agreement to register the resale of the shares of common stock issuable upon conversion of the Series D preferred stock.

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

Updated data show a second partial response in Part B

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

OTC Markets Group Inc.

NEW YORK, Dec. 23, 2021 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market. Advaxis, Inc. previously traded on NASDAQ.

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Company's common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on December 23, 2021 under the symbol ADXS. The Company previously traded on Nasdaq.

Advaxis Announces Acceptance for Trading on the OTCQX

Stockholders approved Proposal 1 in support of Biosight merger

Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation)

Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction

Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter from the Nasdaq Hearings Panel (the “Panel”) providing Advaxis an extension through December 20, 2021, to complete its business combination with Biosight, Ltd. (“Biosight”) and demonstrate compliance with all applicable requirements for initial listing on The Nasdaq Capital Market.

Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements

Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposals Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposals

Advaxis, Inc. Issues Letter to Stockholders

Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight

Combined company, to be named Biosight Therapeutics, expected to be well-positioned to leverage its compelling oncology therapeutics pipeline, strong cash position, and accomplished management and Board to maximize stockholder value

Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger

Powerbridge Technologies Co Ltd

PetVivo Holdings

Why retail traders are watching these penny stocks right now The post 3 Hot Penny Stocks That Retail Traders Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks That Retail Traders Are Watching Right Now

Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders

Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting

MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) issued a report on November 1, 2021, recommending that Advaxis stockholders vote “FOR” the merger of the Company with Biosight and recommends voting “FOR” all proposals, at the Company's Special Meeting scheduled for November 16, 2021.

Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight

Meta Materials

These penny stocks are popular on TikTok, are they on your watchlist? The post Top Penny Stocks to Buy From TikTok?

Top Penny Stocks to Buy From TikTok? 3 That Investors Are Watching

Surgalign Holdings, Inc.

These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals. The post 6 of the Hottest Stocks to Pick Up for Less Than $1 appeared first on InvestorPlace.

6 of the Hottest Stocks to Pick Up for Less Than $1

Color Star Technology

Ebang International Holdings

Which penny stocks are on your November watchlist? The post Best Penny Stocks to Buy Next Month?

Best Penny Stocks to Buy Next Month? 3 You Need to Know About

Ambev

GEE Group

With so many trending penny stocks to buy, which small caps are you watching? The post Top Trending Penny Stocks to Watch Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Trending Penny Stocks to Watch Next Month

Ideanomics Inc

NexGen Energy

These trending penny stocks could be worth adding to your October watchlist, here's why The post 3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Trending Penny Stocks For Your Small-Caps Watchlist Right Now

ReShape Lifesciences

Voyager Therapeutics

Are these high volume biotech penny stocks worth adding to your watchlist right now? The post Top Biotech Penny Stocks to Watch With High Volume Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Biotech Penny Stocks to Watch With High Volume Right Now

BEST Inc - ADR

Sonim Technologies Inc

Can tech penny stocks perform well amidst today's stock market crash? The post 3 Tech Penny Stocks to Watch During the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tech Penny Stocks to Watch During the Market Crash

Celsion

Tellurian

Why investors are watching these 3 penny stocks right now The post Hot Penny Stocks to Add to Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your September Watchlist

Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies

Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update

Denison Mines

Why top investors are watching these penny stocks right now The post 3 Penny Stocks That Top Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Advaxis Stock (ADXS)